Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new clinical trial results show that ibrutinib continues to control Waldenstrom's Macroglobulinemia, with a median overall response rate of 91% after 19 months of treatment. The disease shows sustained benefit in patients who survived for two years.
Uninsured cancer patients pay 2-43 times more than Medicare and private insurers for chemotherapy drugs, according to a new study. The study found significant price differences for expensive and inexpensive drugs alike.
According to a Northwestern University study, nearly 400,000 childhood cancer survivors in the US experience chronic health issues, including mental impairment, anxiety, and physical limitations. The majority face these problems five or more years after diagnosis, highlighting the need for comprehensive care.
Many cancers, including pancreatic cancer, enslave and deform mitochondria to create an environment conducive to tumor growth. Researchers found that blocking this process may lead to the growth of tumors.
Scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma, a deadly type of brain tumor. The new method uses nanotechnology to deliver the microRNA across the blood-brain barrier, targeting multiple oncogenes at once and increasing cancer cell death.
Researchers from USC Norris Comprehensive Cancer Center have discovered that herpesvirus proteins activate the RIG-I receptor through deamidation, a process that could be exploited to bolster immunity against infection. The study identifies the first enzyme responsible for protein deamidation in eukaryotes.
Scientists at CHOP use biodegradable nanoparticles to deliver anticancer drugs selectively to tumors, inhibiting growth and prolonging survival in animal models. The approach exploits the EPR effect, allowing for efficient delivery while avoiding toxicity in healthy tissues.
A new review emphasizes the need to decipher immune response dynamics to enhance cancer immunotherapy. Researchers suggest developing combination therapies and biomarker panels to increase treatment impact, as single biomarkers are unlikely to predict patient responses.
Researchers at UCSF identified a biological escape hatch that explains resistance to targeted drug treatment in lung cancer patients. Combining two compounds, erlotinib and PBS-1086, effectively wipes out cancer cells in mice implanted with cells from drug-resistant tumors.
Researchers at Nanyang Technological University (NTU) have found that Imatinib, a leukemia drug, can prevent and control the growth of colorectal tumours. The study suggests that short-term intermittent chemotherapies could be effective in treating colon cancer, reducing side effects associated with long-term treatment.
A new study provides experimental evidence that a drug inhibiting the EphB-signaling pathway effectively suppresses intestinal tumor development. The study suggests that this knowledge may lead to novel treatments for colorectal cancer patients.
Researchers at the University of Missouri-Columbia found that 6-Thioguanine can change how certain cancer cells function, weakening them so they can be killed by other drugs. This discovery could lead to future cancer treatments using combination therapy.
Low doses of Imatinib can stimulate the bone marrow to produce more innate immune cells, such as neutrophils and macrophages, to combat bacterial infections. This finding suggests that Imatinib or related drugs may be useful in treating a variety of infections in patients with weakened immune systems.
Researchers at Yale University have successfully restored memory and synaptic connections in Alzheimer's mice using the experimental cancer drug AZD05030. The treatment blocks damage caused by amyloid-beta plaques, a hallmark of Alzheimer's disease, and has led to the launch of human trials.
Researchers from Scripps Research Institute have discovered a unique mechanism of borrelidin, a natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects. The study sheds light on the compound's inhibition of protein synthesis by occupying four distinct subsites on tRNA synthetase.
Researchers at Princess Margaret Cancer Centre successfully converted microbubble technology into nanoparticles that retain their imaging properties. The discovery has the potential to enhance drug delivery, prolong tumour visualization, and improve cancer treatment precision.
Researchers at Michigan Medicine have developed a new compound that shows promise in treating acute leukemia and may also play a role in prostate cancer. The MLL-menin interaction is a key driver of the disease, and blocking this interaction has shown potential in laboratory studies.
Researchers have developed an experimental drug, BHPI, that rapidly shrinks most tumors in a mouse model of human breast cancer. The drug works by hyperactivating the unfolded protein response pathway, driving cancer cells from using it for protection into making it a lethal pathway.
Weizmann Institute scientists identified a potential drug molecule that stops cancer cells from getting their 'mail' by blocking communication with the nucleus. This method could treat various cancers and have fewer side effects than current treatments.
A new study suggests that fasting combined with a class of cancer-inhibiting drugs can starve colorectal, breast and lung cancer cells, potentially replacing chemotherapy. The research found that this combination is equally effective in killing cancer cells.
Researchers have discovered a new function for the retinoblastoma gene, which plays a central role in stopping healthy cells from dividing uncontrollably. The gene also helps to mend broken strands of DNA by forming clusters with other proteins, opening up new approaches to cancer treatment.
A new study evaluates currently available screening tools for senior cancer patients taking too many medications. It found that a more comprehensive assessment and monitoring plan is needed to improve treatment outcomes.
A team of Singapore-based scientists identified a new signalling pathway regulating cancer internal diet. The therapy combines an old anti-malarial drug with CK1α inhibition, effectively treating colon and bladder cancers. Researchers hope to develop more potent inhibitors for this treatment.
Researchers discovered that saccharin binds to and deactivates carbonic anhydrase IX, a protein found in some aggressive cancers. This finding opens up the potential to develop novel anti-cancer drugs derived from common condiments.
Researchers found that blocking two pathways, PGE2 and PD-1, boosts T-cell function and enhances viral control in mice with chronic infections. Celecoxib, a non-steroidal anti-inflammatory drug, was also shown to improve T-cell responses.
A new study reveals a blood test that measures circulating tumour cells can predict which men are benefitting least from prostate cancer drug treatment after just 12 weeks. The test may allow doctors to switch patients to alternative treatments earlier, speeding up clinical trials and improving survival rates.
Researchers found that a combination of metformin and vitamin D3 significantly improved outcomes in animal studies, inhibiting tumor growth and reducing polyp formation. The dual-compound effect was more effective than either option alone, with modest amounts needed to achieve the benefits.
Researchers from the University of Melbourne found that genetic variation affects the protective effect of aspirin on bowel cancer risk. The study analyzed data from 8,624 participants and found that about 1 in 25 people do not benefit from taking aspirin, potentially increasing their risk.
Research links genetic changes in bowel tumours to immune system responses, suggesting potential for targeted immunotherapy treatments. Genetic profiles could be used to diagnose suitability for immunotherapies and tailor treatment plans.
Researchers discover that combining Sodium Formate with metal-based cancer treatment JS07 can greatly increase its effectiveness against ovarian cancer cells. The potent form of JS07 disrupts cancer cell's energy generation mechanism, leading to cell shutdown and potential reduction in side effects.
A pioneering class of drugs targeting BRCA breast cancer genes may also work against tumours with CLBC gene defects. Researchers found that CLBC-defective cancer cells are vulnerable to PARP inhibitor drugs, opening up new treatment possibilities for a broader group of patients.
Researchers use mathematical models to characterize tumor microenvironment, highlighting sanctuary sites as key to drug resistance. Tumor sanctuaries with little drug exposure are the source of resistant mutants.
Researchers aim to target autophagy pathway, a key enzyme involved in cancer and neurodegenerative diseases. They plan to use high-throughput screening facilities to identify new inhibitors of Ulk1, a critical on-off switch regulating the pathway.
A study published in JAMA found significant discrepancies in diagnoses of atypia and DCIS, highlighting the need for women to seek second opinions. The study involved 115 pathologists and 6,900 breast biopsy interpretations, revealing a concordance rate of 75.3% for invasive carcinoma but only 48% for atypia.
A Dartmouth investigator found an mHealth app acceptable to diverse and low-income women for breast health risk assessment. The study showed that 11 of the 15 participants preferred using the mobile health device over a paper tool.
Washington State University researchers have discovered a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings suggest that a potential new anti-cancer drug could be developed to target this process.
A new international study has found a small subset of patients with adrenal cancer respond significantly to the investigational drug linsitinib, paving the way for personalized treatment options. The researchers plan to analyze DNA collected from the study to identify possible markers for response.
A study by MIT economist Ernst Berndt and colleagues found that the prices of leading cancer drugs increased by 10% annually from 1995 to 2013, even after adjusting for inflation and incremental health benefits. The researchers suggest that rising prices reflect a greater social tolerance for significant healthcare costs.
A study published in Nature Reviews Immunology reveals a 'window of vulnerability' for sexually transmitted infections (STIs) to infect the female reproductive tract. The researchers found that hormonal changes during the menstrual cycle create an optimal environment for implantation, which also increases susceptibility to STIs.
Researchers have developed spherical nucleic acids that can selectively trigger the immune response, potentially treating a range of diseases including psoriasis, lupus, rheumatoid arthritis, lymphoma, bladder cancer, and prostate cancer. SNAs are nontoxic, potent, and efficiently deliver nucleic acids into cells via the endosome.
A new study from the University of British Columbia suggests that Canada can implement universal public drug coverage without increasing taxes. The study estimates that this system would save the Canadian economy $7.3 billion annually by increasing the use of generic drugs and negotiating lower prices with pharmaceutical companies.
A study by Mayo Clinic Cancer Center reveals the average price of cancer drugs in the US has increased significantly over the years, affecting patient care. The authors recommend six potential solutions to control high drug costs, including allowing Medicare to negotiate prices and implementing value-based pricing.
Pazopanib, a cancer drug, shows promise in reducing bleeding and small AVMs in patients with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. The study aims to assess the efficacy of pazopanib in improving symptoms and quality of life for HHT patients.
A genetically engineered immunotoxin called DT2219 has shown safety and clinical effectiveness in a phase I trial for patients with relapsed/refractory B-cell malignancies. Two patients achieved durable objective responses, highlighting the potential of this new treatment approach.
The NCCN Clinical Practice Guidelines in Oncology provide evidence-based recommendations for smoking cessation in patients with cancer. Combining pharmacologic therapy and counseling is the most effective approach, leading to improved cancer treatment effectiveness and decreased recurrence.
Researchers found that combining naproxen with omeprazole reduced bladder cancer incidence by 75% in rats. This combination may be a valuable cancer prevention strategy for those at high risk of colon, esophageal, or other cancers.
Researchers have developed a new light therapy that can reach deep tumors using nanoparticles and FDG, producing different kinds of free radicals that overwhelm tumor cells. This treatment shows promise in reducing cancer growth and increasing survival rates with minimal toxic side effects.
A Review article discusses how existing drugs like Viagra can reduce the activity of a specific chaperone protein, HSPA5/Dna K, which may lead to anti-tumor and anti-Alzheimer's disease effects. The study also reveals potential applications in treating antibiotic-resistant infections and chemotherapy-resistant cancers.
A new study has identified two distinct subtypes of childhood leukemia and found that about 13 percent of ALL cases may be successfully treated with targeted drugs. The research developed a simple lab test to determine which patients fall into the less-common subtype, opening up new hope for treatment options.
Researchers at Scripps Research and Mayo Clinic have identified a new class of senolytic drugs that can slow the aging process. These compounds, dasatinib and quercetin, selectively induce death in senescent cells, leading to improved cardiovascular function, exercise endurance, and extended healthspan.
A phase 2 clinical trial found that sunitinib significantly improved progression-free survival in patients with advanced differentiated thyroid cancer. The study showed that 83% of patients benefited from treatment, with either tumor shrinkage or slowed disease progression.
Researchers from Boston University School of Medicine shed new light on tumor metastasis, proposing a hypothesis that reversible epigenetic events regulate different types of metastatic cancers. Epigenetics enables cancer progenitor cells to differentiate into metastatic tumors.
A new study from Dana-Farber Cancer Institute found that many websites marketing personalized cancer care services make exaggerated claims, with 88% offering nonstandard tests lacking clear clinical utility. The researchers urge consumers and healthcare providers to critically evaluate these services.
Researchers at UC Davis have discovered a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. This mechanism was found to be effective against glioma cells, which are responsible for a usually fatal type of brain cancer, and could be applicable to other highly aggressive cancers.
Researchers investigated a potential link between new weight-loss drugs and increased colon cancer risk, driven by the intestinal growth factor properties of glucagon-like peptide-1 (GLP-1). The study suggests that patients with a previous history or increased risk of colon cancer may not be ideally suited for these therapies.
Intermediate filaments of vimentin 'insulate' mitochondria in cancer cells from destruction, preserving energy reserves. This discovery may lead to the development of new drugs that effectively treat cancer.
Researchers found that a secreted immune protein called interleukin(IL)-17B promotes pancreatic cancer growth and metastasis. Treating tumor-bearing mice with an IL-17B inhibitor halted tumor growth and spread, resulting in increased survival.
A recent study by Samir Soneji found that the US spends significantly more on cancer treatment than Western European countries, yet mortality rates have decreased only modestly since 1970. The study suggests that much of this spending may be unnecessary and not leading to significant quality-adjusted-life-year gains.
A new nanodevice developed by MIT researchers can block the gene that confers drug resistance and then deliver a chemotherapy attack against disarmed tumors. The device was tested in mice implanted with human breast tumors and successfully shrunk tumors by 90% in two weeks.
Chemists at Bielefeld University develop copper-based anti-tumor agent that targets DNA phosphates, disrupting cellular processes and killing cancer cells. The new agent shows higher efficacy than cisplatin in killing cancer cells at lower concentrations.